inMIND
inMIND: A Phase III Study of Tafasitamab, an Anti-CD19 Antibody, Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma

Released: December 12, 2024

Expiration: December 11, 2025

Activity

Progress
1
Course Completed